TW200306811A - Medicinal compositions for inhibiting tryptase - Google Patents

Medicinal compositions for inhibiting tryptase Download PDF

Info

Publication number
TW200306811A
TW200306811A TW092103438A TW92103438A TW200306811A TW 200306811 A TW200306811 A TW 200306811A TW 092103438 A TW092103438 A TW 092103438A TW 92103438 A TW92103438 A TW 92103438A TW 200306811 A TW200306811 A TW 200306811A
Authority
TW
Taiwan
Prior art keywords
tryptase
disease
item
par
pharmaceutical composition
Prior art date
Application number
TW092103438A
Other languages
English (en)
Chinese (zh)
Inventor
Ryozo Oishi
Yoshinori Ito
Toshiaki Sendo
Original Assignee
Torii Yakuhin K K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Torii Yakuhin K K filed Critical Torii Yakuhin K K
Publication of TW200306811A publication Critical patent/TW200306811A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW092103438A 2002-02-22 2003-02-19 Medicinal compositions for inhibiting tryptase TW200306811A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002046613A JP2003246730A (ja) 2002-02-22 2002-02-22 トリプターゼ阻害剤

Publications (1)

Publication Number Publication Date
TW200306811A true TW200306811A (en) 2003-12-01

Family

ID=27750646

Family Applications (1)

Application Number Title Priority Date Filing Date
TW092103438A TW200306811A (en) 2002-02-22 2003-02-19 Medicinal compositions for inhibiting tryptase

Country Status (4)

Country Link
JP (1) JP2003246730A (enExample)
AU (1) AU2003211540A1 (enExample)
TW (1) TW200306811A (enExample)
WO (1) WO2003070235A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120491A1 (ja) * 2004-06-14 2005-12-22 Torii Pharmaceutical Co., Ltd. 炎症性腸疾患の治療薬又は予防薬
GB0507577D0 (en) * 2005-04-14 2005-05-18 Novartis Ag Organic compounds
US20090088472A1 (en) * 2005-05-17 2009-04-02 Kouji Oohashi Protective Agent for Neuronal Cell Comprising Amidino Derivative as Active Ingredient
JP2007186457A (ja) * 2006-01-13 2007-07-26 Ichimaru Pharcos Co Ltd トリプターゼ活性阻害剤およびその利用
GB2445920A (en) * 2007-01-25 2008-07-30 Mucokinetica Ltd Amidino compounds for treatment of respiratory disease
CN106580961A (zh) * 2016-12-07 2017-04-26 郑州仁宏医药科技有限公司 一种用于治疗特发性肺纤维化的西药组合及其应用
KR20220098056A (ko) * 2018-02-09 2022-07-08 제넨테크, 인크. 비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
EP4126054A4 (en) * 2020-03-31 2024-05-15 Ensysce Biosciences, Inc. METHOD OF TREATING VIRUS INFECTIONS WITH NAFAMOSTAT

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5753454A (en) * 1980-09-16 1982-03-30 Torii Yakuhin Kk Guanidinobenzoate and anticomplementary agent
EP0893437A4 (en) * 1996-04-10 2000-12-27 Ono Pharmaceutical Co GUANIDINO TRYPTASE INHIBITOR

Also Published As

Publication number Publication date
WO2003070235A1 (en) 2003-08-28
JP2003246730A (ja) 2003-09-02
AU2003211540A1 (en) 2003-09-09

Similar Documents

Publication Publication Date Title
ES2565519T3 (es) Antagonista del receptor de angiotensina II para el tratamiento de la enfermedad cardiovascular en gatos
AU2002328494B2 (en) Drugs containing chymase inhibitor and ACE inhibitor as the active ingredients
JP2003535034A (ja) ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法
US20080058303A1 (en) Use of melagatran
CA3113376A1 (en) Compositions for reducing serum uric acid
CA2685446A1 (en) Pharmaceutical composition comprising at least one thrombolytic agent (a) and at least one gas (b) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon
JP2007523056A5 (enExample)
BR112021006132A2 (pt) compostos bifenil sulfonamida para o tratamento de doenças de colágeno tipo iv
JP2003246730A (ja) トリプターゼ阻害剤
WO1997035609A1 (en) Neovascularization inhibitor containing tissue factor pathway inhibitor
JPH11269076A (ja) 抗線維化剤
CN114423461A (zh) 组合
KR101086040B1 (ko) 간섬유화 및 간경화 치료 효과를 갖는 아시아트산 유도체
JP4686704B2 (ja) 動脈瘤予防および／または治療剤
CN101301467A (zh) Bmp-7在制备预防和/或治疗肝纤维化药物中的应用
WO2026082873A1 (en) Use of caspase-1 inhibitors for treating ineffective erythropoiesis in patients suffering from sickle cell disease
WO2007020509A1 (en) Combination of methylol transfer agents with tumour-inhibiting proteins or peptides and the use thereof for the treatment of cancer or tumor growth
WO2023230593A1 (en) Ptp1b inhibitors for treating lung injury
Taylor et al. Hyperkalemia with concomitant watery diarrhea: an unusual association
RU2402329C2 (ru) Применение триоксопиримидина для лечения и предупреждения воспалительных заболеваний бронхов
CN119318654A (zh) 氟达拉滨和替莫唑胺联用在治疗脑胶质瘤中的应用
CA3192119A1 (en) Therapeutic compounds, compositions, and methods of use thereof
JP2023518281A (ja) コロナウイルス生存率改善のためのｃａｒペプチド
CN116782911A (zh) 治疗性化合物、组合物及其使用方法
MXPA01007003A (es) Nuevo uso del melagatran